Oasis Capital's Early Investment *Yixi Bio* Closes Nearly 100 Million RMB Pre-A+ Round | Oasis Vitality

Yixi Biotech, a technology company focused on synthetic biology innovation and product R&D, recently completed a Pre-A+ round of nearly RMB 100 million. The round was led by Huangpu Biotech, with participation from Oriza Holdings, Junzi Capital, Yizhan Capital, and Liding Capital. Existing shareholders Oasis Capital and Shenzhen HTIC also continued to invest.

According to the company, the proceeds will primarily fund process iteration and industrialization of its existing pipeline, as well as R&D for new product lines.

Yixi Biotech is among the first Chinese companies to achieve industrial-scale production of human milk oligosaccharides (HMOs) through synthetic biology. As the third most abundant component in human breast milk, HMOs have been scientifically validated to block pathogens, promote beneficial bacteria growth, strengthen immunity, reinforce intestinal barriers, reduce diarrhea and respiratory infections, lower the risk of food allergies and eczema, and support brain development. Adding HMOs effectively narrows the gap between infant formula and human breast milk, and they are already used in many international formula brands. Beyond infant formula, HMOs can also be applied in probiotics, dietary supplements, functional foods, and foods for special medical purposes.

The production facility, operated by Yixi Biotech's wholly-owned subsidiary Huangshan Tongxi Biotechnology, is located in Huangshan, Anhui province. It is China's first and only HMOs production plant, with current installed capacity of 300 tons and expansion ports that allow rapid scaling to 3,000 tons per year based on market demand. A reserved Phase II is planned for 10,000 tons per year across nine HMOs subcategories. Since the facility's delivery in March this year, it has successfully completed stable, continuous trial production and provided qualified research samples at the ton scale. To date, the company has established partnerships with multiple downstream enterprises both domestically and internationally, and has also collaborated with relevant research institutions on application-side studies.

Yixi Biotech's second product pipeline is single-cell protein (SCP) for animal feed. Using non-grain raw materials — specifically lignocellulose from crop stalks — as a carbon source, the company produces single-cell protein through combined microbial fermentation to serve as feed protein for pigs, chickens, cattle, and sheep. This reduces dependence on imported soybeans and contributes to national food security. China imports nearly 100 million tons of soybeans annually, spending over RMB 400 billion, with a high degree of import reliance. The biggest challenge in replacing imported soybeans with microbial protein as a feed source is cost. Yixi Biotech has significantly reduced production costs through innovations in strain isolation, domestication, co-cultivation, and multiple process technologies. This pipeline is expected to reach industrialization next year.

Yixi Biotech insists on driving product R&D and manufacturing through solid scientific research and technological innovation. While developing products, the company continuously explores underlying technologies and the logic of life itself. In terms of product portfolio, it uses food additives as an entry point while advancing multiple pipelines in parallel. While diligently building products, Yixi Biotech remains mindful of the mission entrusted by the era, persisting in technological innovation and transformation with the aspiration to become a great technology enterprise.

After years of rapid expansion, synthetic biology has entered a new phase where it must "bear fruit" to prove itself, and industrialization will become the industry's new foundation. Going forward, the shift from "where to go" to "how to get there" is something many practitioners will need to focus on.

Yixi Biotech maintains that still waters run deep. The company will continue steadily, adhering to the principle of "quality over quantity," pushing products from the "laboratory" to the "factory." It firmly believes that cost is the key to successful industrialization, and plans to achieve its established goal of "three industrialized products" within the next three years.

Oasis Capital is a new-generation venture capital firm in China, dedicated to discovering the most vital entrepreneurs of the next decade and growing alongside them to create long-term value. "Cultivating Vitality" is Oasis Capital's vision and mission. This vitality is both the direction of structural transformation in the era and the resilient, evolving force of entrepreneurs themselves.

Oasis Capital focuses on early and growth-stage investments, with individual ticket sizes ranging from $3 million to $30 million. It concentrates on technology-enabled sectors including healthcare, biotechnology, and enterprise services, supporting the upgrade of China's technology-driven new services.